Orphan medications are drugs that are developed for the treatment of rare diseases and situations. Tourette syndrome, Huntington's disease, muscular dystrophy, myoclonus, and ALS (Lou Gehrig's disease) are examples of uncommon disorders for which no appropriate medications have been produced, and thus these diseases are treated using orphan drugs. Orphan medications are produced by pharmaceutical corporations to meet a public health need, and their sales are very low when compared to standard drugs. Patients with orphan diseases account for 6-8 percent of the global population. Some orphan diseases, such as cystic fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and others, have symptoms that occur at birth or in childhood.
The orphan drugs market into five regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. North America dominates the global market due to factors such as a well-established regulatory and reimbursement system, as well as incentives provided by the US Food and Drug Administration (FDA) for orphan drug research and development. The orphan drug industry is boosted by different joint research programmes across the United States and Europe that deliver research data on rare diseases to producers, patients, and health specialists, allowing for prompt medical care. The incidence of genetic illnesses and population expansion are two variables that may encourage orphan medicine companies to invest in the Asia Pacific area.
Click here for Orphan Drugs Market Report: